Sugi Predict

Sugi Predict / Compounds / SCHEMBL673213

SCHEMBL673213

SCHEMBL673213

CCCCCCO[PH](=O)OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 8/20 0.39
▸ CA2 P00918 8/20 0.39
▸ CA9 Q16790 7/20 0.39
▸ LPAR3 Q9UBY5 3/20 0.39
▸ CA12 O43570 3/20 0.39
▸ CA7 P43166 3/20 0.39
▸ CA14 Q9ULX7 3/20 0.39
▸ LPAR1 Q92633 2/20 0.39
▸ LPAR2 Q9HBW0 2/20 0.39
▸ CA3 P07451 2/20 0.39
▸ CA4 P22748 2/20 0.39
▸ CA6 P23280 2/20 0.39
▸ CA5A P35218 2/20 0.39
▸ CA5B Q9Y2D0 2/20 0.39
▸ NAAA Q02083 1/20 0.39
▸ RECQL P46063 2/20 0.38
▸ TSHR P16473 2/20 0.38
▸ CES2 O00748 1/20 0.38
▸ GLA P06280 1/20 0.38
▸ HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27619571 1.00 CA1 (0.39) CA1CA2CA9LPAR3CA12
SCHEMBL254498 1.00 CA1 (0.39) CA1CA2CA9LPAR3CA12
SCHEMBL27619508 1.00 CA1 (0.39) CA1CA2CA9LPAR3CA12
SCHEMBL13808349 1.00 CA1 (0.39) CA1CA2CA9LPAR3CA12
SCHEMBL7453879 1.00 CA1 (0.39) CA1CA2CA9LPAR3CA12
SCHEMBL21569450 1.00 CA1 (0.39) CA1CA2CA9LPAR3CA12
SCHEMBL21569451 1.00 CA1 (0.39) CA1CA2CA9LPAR3CA12
SCHEMBL21569447 1.00 CA1 (0.39) CA1CA2CA9LPAR3CA12
SCHEMBL21569437 1.00 CA1 (0.39) CA1CA2CA9LPAR3CA12
Water SCHEMBL7644684 0.98 CA1 (0.38) CA1CA2CA9LPAR3CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0994128-B1 Process and iron-based catalyst composition for the production of syndiotactic 1,2-polybutadiene BRIDGESTONE CORP (JP) 2007-08-01 — — EP claimed
US-6620760-B2 Coordination catalyst BRIDGESTONE CORPORATION (JP) 2003-09-16 — — US claimed
US-20230130333-A1 METHOD FOR MANUFACTURING PHOSPHONATE ESTERS AND METHOD FOR MANUFACTURING PHOSPHATE ESTERS FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2023-04-27 — — US disclosed
CN-107148441-B Polyolefin resin pre-expanded particles, in-mold expanded molded article, and methods for producing these 钟化比利时公司 2020-11-27 — — CN disclosed
CN-109689027-A Triglycerides aural preparations and application thereof 奥德纳米有限公司 2019-04-26 — — CN disclosed
CN-104491864-A Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders OTONOMY INC 2015-04-08 — — CN disclosed
CN-102014957-B Otic formulations for the treatment of otic diseases and conditions OTONOMY INC 2014-12-10 — — CN disclosed
US-20120252979-A1 Process for Producing Blends of Syndiotactic, 1,2-Polybutadiene and Rubbery Elastomers RADEMACHER CHRISTINE (US) 2012-10-04 — — US disclosed
US-8067503-B2 Process for producing blends of syndiotactic, 1,2-polybutadiene and rubbery elastomers BRIDGESTONE CORPORATION (JP) 2011-11-29 — — US disclosed
CN-102014957-A Otic formulations for the treatment of otic diseases and conditions OTONOMY INC 2011-04-13 — — CN disclosed
EP-1476480-B1 POLYMERIZATION PROCESS FOR PREPARING SYNDIOTACTIC 1,2-POLYBUTADIENE BRIDGESTONE CORP (JP) 2009-07-22 — — EP disclosed
WO-2000075201-A1 MOLYBDENUM-BASED CATALYST COMPOSITION FOR POLYMERIZING CONJUGATED DIENES BRIDGESTONE CORPORATION (JP) 2000-12-14 — — WO disclosed
EP-0994129-A1 Iron-based catalyst composition and process for producing syndiotactic 1,2-polybutadiene Bridgestone Corporation (JP) 2000-04-19 — — EP disclosed
EP-0994127-A1 Method of preparing syndiotactic 1,2-polybutadiene with a chromium-based catalyst system Bridgestone Corporation (JP) 2000-04-19 — — EP disclosed
EP-0994128-A1 Process and iron-based catalyst composition for the production of syndiotactic 1,2-polybutadiene Bridgestone Corporation (JP) 2000-04-19 — — EP disclosed
US-5919875-A ORGANOALUMINUM HYDRIDE, ORGANIC HYDROGEN PHOSPHITE BRIDGESTONE CORPORATION (JP) 1999-07-06 — — US disclosed
EP-0926167-A1 Preparation of syndiotactic 1,2-polybutadiene using a chromium-containing catalyst system Bridgestone Corporation (JP) 1999-06-30 — — EP disclosed
US-4168357-A Preparation of high cis-1,4-polypentadiene THE GOODYEAR TIRE & RUBBER COMPANY (US) 1979-09-18 — — US disclosed
US-4168374-A POLYMERIZATION OF PENTADIENE THE GOODYEAR TIRE & RUBBER COMPANY (US) 1979-09-18 — — US disclosed
US-4148983-A TERTIARY CATALYST SYSTEM INCLUDING AN ORGANOMETALLIC COMPOUND, A CHROMIUM COMPOUND AND AN ORGANIC PHOSPHITE THE GOODYEAR TIRE & RUBBER COMPANY (US) 1979-04-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230130333-A1 METHOD FOR MANUFACTURING PHOSPHONATE ESTERS AND METHOD FOR MANUFACTURING PHOSPHATE ESTERS PHOSPHO1, PHYKPL, PIK3CA CA1 775/4885CA2 1867/4885CA9 604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.